University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Phase 1

Recruiting

Conditions: Gaucher Disease, Type 2
Wolman Disease
MPS II
MPS IVA
MPS VI
Mps VII
Pompe Disease Infantile-Onset
MPS I
Gaucher Disease, Type 3

Interventions: Drug: Aldurazyme (laronidase)

First Posted Date: 2020-08-31

Last Posted Date: 2025-03-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT04532047

Locations: 🇺🇸
University of California, San Francisco, California, United States

Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins

Completed

Conditions: Therapeutic Proteins
Asthma

First Posted Date: 2020-08-17

Last Posted Date: 2025-04-01

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 62

Registration Number: NCT04514926

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study of Focal Airway Disease in Asthma Using Image Guided Bronchoscopy

Withdrawn

Conditions: Asthma
Mucus; Plug, Tracheobronchial

Interventions: Radiation: Multidetector Computed Tomography (MDCT) Scan
Procedure: Virtual Navigation Bronchoscopy (VNB)

First Posted Date: 2020-08-17

Last Posted Date: 2023-02-21

Lead Sponsor: University of California, San Francisco

Registration Number: NCT04514913

Locations: 🇺🇸
UCSF Airway Clinical Research Center, San Francisco, California, United States

Foster Care Mental Health Family Navigator

Not Applicable

Recruiting

Conditions: Mental Health

Interventions: Behavioral: Family-based mental health navigation
Behavioral: Standard of care engagement practices

First Posted Date: 2020-08-10

Last Posted Date: 2023-05-11

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 125

Registration Number: NCT04506437

Locations: 🇺🇸
UCSF Zuckerberg San Francisco General Hospital, San Francisco, California, United States

CT Guided CI Programming

Not Applicable

Completed

Conditions: Amusia
Cochlear Implants
Hearing Loss

Interventions: Other: CT Guided Cochlear Implant Programming

First Posted Date: 2020-08-10

Last Posted Date: 2025-05-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 19

Registration Number: NCT04506424

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Family Telehealth Project for Foster Care Youth

Not Applicable

Recruiting

Conditions: Parent-Child Relations
Communication

Interventions: Behavioral: Family-based Telehealth Intervention

First Posted Date: 2020-07-28

Last Posted Date: 2024-05-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 300

Registration Number: NCT04488523

Locations: 🇺🇸
UCSF Zuckerberg San Francisco General Hospital, San Francisco, California, United States

Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Phase 4

Completed

Conditions: Drug-Drug Interaction
HIV Infection

Interventions: Drug: Dihydroartemisinin-piperaquine

First Posted Date: 2020-07-27

Last Posted Date: 2025-03-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 194

Registration Number: NCT04487145

Locations: 🇺🇬
Masafu General Hospital (MGH) at Busia District, Eastern Uganda, Masafu, Busia, Uganda
🇺🇬
Baylor-Uganda Center of Excellence on Mulago Hospital Complex and Masafu General Hospital, Kampala, Uganda

DISulfiram for COvid-19 (DISCO) Trial

Phase 2

Terminated

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Disulfiram

First Posted Date: 2020-07-24

Last Posted Date: 2023-09-13

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 11

Registration Number: NCT04485130

Locations: 🇺🇸
University of California San Francisco, Fresno, Fresno, California, United States
🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1

Recruiting

Conditions: High Grade Glioma
Low-grade Glioma
Recurrent World Health Organization (WHO) Grade II Glioma

Interventions: Drug: Everolimus
Drug: Trametinib

First Posted Date: 2020-07-24

Last Posted Date: 2025-06-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT04485559

Locations: 🇺🇸
University of Alabama at Birmingham, Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Diego Rady Children's Hospital, San Diego, California, United States

and more 14 locations

Induced Pluripotent Stem Cells for Disease Research

Completed

Conditions: Hirschsprung Disease

First Posted Date: 2020-07-20

Last Posted Date: 2022-10-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 1

Registration Number: NCT04476225

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy